Bristol Myers Squibb (BMY): analysis in plain words
Is Bristol Myers Squibb cheap or expensive? How it makes money, whether it grows and its risks, explained in plain words and with its official accounts.
Bristol Myers Squibb (BMY) is listed on the NYSE and we classify it in healthcare and pharma. Below are its key dated figures, how it makes money, how it compares with its sector, what works for and against Bristol Myers Squibb according to those figures, and the questions people ask most about the stock. No buy or sell tips.
Bristol Myers Squibb (BMY) key figures as of November 4, 2026
| Figure | Value | What it measures |
|---|---|---|
| Share price | $64.19 | Last price on November 4, 2026 |
| P/E ratio (TTM) | 14.2x | Price over earnings per share |
| Revenue growth | +6.9% | Latest quarter vs the same quarter a year earlier |
| Net margin (TTM) | 18.5% | Profit for every 100 of sales |
| Net debt / EBITDA | 1.8x | Years of operating profit to repay debt |
| Dividend yield | 4.08% | Annual dividend over price |
| Market cap | $131.2 billion | What the stock market values it at |
The Bristol Myers Squibb figures come from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026. Any BMY figure that is not available shows as N/A: we do not estimate it.
How Bristol Myers Squibb makes money
Bristol Myers Squibb sells prescription drugs in a single segment. Its biggest products are Eliquis, a blood thinner marketed with Pfizer, and Opdivo, a cancer immunotherapy, along with Revlimid, Pomalyst, Breyanzi, Camzyos and the schizophrenia drug Cobenfy. The United States generates most of its revenue.
Over the last 12 months, Bristol Myers Squibb brought in revenue of $50.0 billion. For every 100 it sells, Bristol Myers Squibb keeps 70.5 after the direct cost of what it sells (gross margin) and 33.8 after all operating costs (operating margin).
Bristol Myers Squibb against its sector
To know whether a Bristol Myers Squibb figure is high or low you have to put it next to similar companies. This table compares Bristol Myers Squibb with the median of the 30 healthcare and pharma companies Fintols covers, with data as of November 4, 2026.
| Figure | Bristol Myers Squibb | healthcare and pharma median |
|---|---|---|
| P/E | 14.2x | 31.3x (30) |
| Revenue growth | +6.9% | +8.3% (33) |
| Net margin | 18.5% | 14.9% (33) |
| Dividend yield | 4.08% | 1.52% (33) |
| Net debt / EBITDA | 1.8x | 1.6x (31) |
In short, against the typical healthcare and pharma company, Bristol Myers Squibb trades on a lower P/E, grows more slowly and earns a wider margin. By size, Bristol Myers Squibb ranks number 16 of 28 healthcare and pharma companies quoted in USD on Fintols.
The bull case for Bristol Myers Squibb
What works in favour of Bristol Myers Squibb, according to its figures as of November 4, 2026:
- On a P/E basis Bristol Myers Squibb trades cheaper than its sector: 14.2x its annual earnings, against 31.3x for the healthcare and pharma median (30 companies with data).
- Bristol Myers Squibb earns 44.0% a year on its shareholders' money (return on equity).
The main risk for Bristol Myers Squibb
The Bristol Myers Squibb figures as of November 4, 2026 show no clear red flag (no heavy debt, no losses, no falling sales). Its main risk is the one built into its business: a key drug losing patent protection or a clinical trial failing, plus government pressure on prices.
Frequently asked questions about Bristol Myers Squibb
Is it a good time to buy Bristol Myers Squibb stock?
Fintols does not tell you whether to buy or sell Bristol Myers Squibb, and nobody knows what the price will do tomorrow. What we can show you is where it stands today. As of November 4, 2026, Bristol Myers Squibb stock trades at $64.19, 6% below its 52-week high ($68.64) and 42% above its low ($45.27). Its P/E is 14.2x against a healthcare and pharma median of 31.3x, and 9.6x on the earnings analysts expect over the next 12 months. With Bristol Myers Squibb, as with any stock, timing matters less than understanding the business, investing for the long run and not betting everything on a single company.
Does Bristol Myers Squibb pay a dividend?
Yes. As of November 4, 2026, Bristol Myers Squibb pays $2.52 per share a year, which at today's price is a yield of 4.08%. It uses 56% of its profit to pay it, which leaves room to keep paying it if profit dips.
Is Bristol Myers Squibb stock expensive?
It depends on what you compare it with. On P/E, Bristol Myers Squibb trades at 14.2x its last 12 months of earnings: cheaper than the healthcare and pharma median (31.3x). A high P/E alone does not make Bristol Myers Squibb expensive: it can be justified if earnings grow fast, and a low one can reflect a business in trouble.
Who are Bristol Myers Squibb's competitors?
On Fintols we compare Bristol Myers Squibb with CVS Health, Danaher and Gilead, which are also in healthcare and pharma. As of November 4, 2026, CVS Health is worth $102.3 billion and trades on a P/E of 21.0; Danaher is worth $165.2 billion and trades on a P/E of 38.9; Gilead is worth $216.4 billion. Each has a side-by-side comparison with Bristol Myers Squibb below.
Bristol Myers Squibb competitors
- CVS Health (CVS) analysis · Bristol Myers Squibb vs CVS Health comparison
- Danaher (DHR) analysis · Bristol Myers Squibb vs Danaher comparison
- Gilead (GILD) analysis · Bristol Myers Squibb vs Gilead comparison
To understand Bristol Myers Squibb better
- DCF and WACC Explained: A Practical Valuation Guide
- Dividend Growth Investing: FCF Payout Ratio and Compounding
More companies like Bristol Myers Squibb: healthcare and pharma stocks, S&P 500 companies and S&P 100 companies. Open the full BMY analysis with its valuation and scenarios. Educational content about Bristol Myers Squibb, not investment advice.